Grafalon Sct

Grafalon Sct is a rabbit-derived anti‑T‑lymphocyte immunoglobulin formulated as a sterile solution for injection. The product contains polyclonal antibodies that target human T‑lymphocyte surface antigens. It is supplied in a standard concentration for intravenous administration and is classified as a prescription immunosuppressant used in transplant medicine. It is authorized for use within the European Union and is indicated for specific post‑transplant immunologic conditions in clinical practice.

Grafalon Sct is employed in transplant and hematopoietic settings to modulate cellular immunity.

- Prevention of acute organ‑allograft rejection in kidney, liver, heart or lung transplantation. - Treatment of graft‑versus‑host disease (GVHD) following allogeneic stem cell transplantation. - Induction therapy to reduce the risk of early immune activation after transplantation. - Adjunctive immunosuppression in patients who are at high immunologic risk.

The immunologic activity of Grafalon Sct can produce a range of adverse reactions, which are generally categorized by frequency and severity.

Common: - Fever, chills or rigors during infusion. - Nausea, vomiting or mild abdominal discomfort. - Transient leukopenia or lymphopenia. - Mild hypotension or flushing.

Serious: - Severe infusion‑related reactions such as anaphylaxis. - Cytokine release syndrome with high fever and hypotension. - Opportunistic infections including viral, bacterial or fungal pathogens. - Hemolytic anemia or thrombocytopenia. - Serum sickness–like reactions.

Clinicians should evaluate several safety considerations before initiating Grafalon Sct therapy.

- Baseline complete blood count and differential to assess lymphocyte levels. - Screening for active infections, especially viral hepatitis, CMV, or HIV. - Monitoring of renal and hepatic function during treatment. - Caution in patients with a history of hypersensitivity to rabbit proteins. - Avoid use in pregnant or breastfeeding individuals unless benefits clearly outweigh risks. - Consider prophylactic antimicrobial therapy to reduce infection risk. - Observe for signs of cytokine release during the first infusion.

Grafalon Sct may interact with other agents that affect immune function or hemodynamics.

Avoid: - Concurrent use of other T‑cell depleting antibodies or potent immunosuppressants without dose adjustment. - Live vaccines administered during or shortly after therapy. - High‑dose corticosteroids given simultaneously without monitoring.

Use with caution: - Calcineurin inhibitors (e.g., cyclosporine, tacrolimus) due to additive nephrotoxicity. - Antiviral agents that require dose modification in immunocompromised patients. - Hematopoietic growth factors such as G‑CSF, which may alter leukocyte recovery. - Diuretics that can exacerbate infusion‑related hypotension.